Prokidney Corp (PROK) - News Archive

The landscape of chronic kidney disease (CKD) therapeutics is rapidly evolving, with emerging cell therapies offering new hope for patients suffering from advanced stages of the disease. At the forefront of this innovat...

ProKidney Corp Announces Successful Closing of $140 Million Public Offering and Registered Direct OfferingProKidney Corp, a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, ha...

ProKidney Corp. Announces $125 Million Public Offering to Advance Treatment for Chronic Kidney DiseaseProKidney Corp., a leading cellular therapeutics company specializing in chronic kidney disease, has just announced a...

Renal Autologous Cell Therapy Shows Promise: Interim Results from ProKidney s REGEN-007 Phase 2 Trial Authors: Author Names, CSIMarket.com In a recent announcement, ProKidney Corp. (Nasdaq: PROK), a prominent late clini...

ProKidney Corp. Reports Positive Business Updates and First Quarter Financial ResultsProKidney Corp., a renowned late-stage cellular therapeutics company specializing in chronic kidney disease (CKD), has recently releas...

ProKidney Strengthens Clinical and Technical Operations with Key Leadership AppointmentsProKidney, a prominent player in the healthcare sector, has recently announced significant leadership appointments aimed at bolster...